BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 37564898)

  • 1. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.
    Ajufo HO; Waksal JA; Mascarenhas JO; Rampal RK
    Ther Adv Hematol; 2023; 14():20406207231177282. PubMed ID: 37564898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of advanced phase myeloproliferative neoplasms.
    Marcellino B; Mascarenhas J
    Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 6. Accelerated and blast phase myeloproliferative neoplasms.
    Saliba AN; Gangat N
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
    Chen D; Fuda F; Weinberg O
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
    Tefferi A; Alkhateeb H; Gangat N
    Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
    Marcellino BK; Hoffman R; Tripodi J; Lu M; Kosiorek H; Mascarenhas J; Rampal RK; Dueck A; Najfeld V
    Blood Adv; 2018 Dec; 2(24):3581-3589. PubMed ID: 30563882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are the molecular mechanisms driving the switch from MPNs to leukemia?
    Wang X; Hoffman R
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
    Bewersdorf JP; Rampal RK
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
    Patel AA; Yoon JJ; Johnston H; Davidson MB; Shallis RM; Chen EC; Burkart M; Oh TS; Iyer SG; Madarang E; Muthiah C; Gross I; Dean R; Kassner J; Viswabandya A; Madero-Marroquin R; Rampal RK; Guru Murthy GS; Bradley TJ; Abaza Y; Garcia JS; Gupta V; Pettit KM; Cursio JF; Odenike O
    Blood Adv; 2024 May; ():. PubMed ID: 38739724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
    Liisborg C
    Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
    Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
    Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
    Khan M; Siddiqi R; Gangat N
    Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
    Yogarajah M; Tefferi A
    Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
    Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
    Int J Lab Hematol; 2024 Apr; ():. PubMed ID: 38665121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease modifying agents of myeloproliferative neoplasms: a review.
    Lee SE
    Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.